Malaria Global update, progress, priorities Steve Taylor GLHLTH701 Sept 2 2014
Dec 21, 2015
MalariaGlobal update, progress, priorities
Steve TaylorGLHLTH701Sept 2 2014
Overview
• Malaria– Microbiologically, epidemiologically– Historically, clinically
• Malaria today• Progress• Hot topics
– Vaccines– Drug resistance
What is malaria?
What is malaria?
Homo sapiens and Plasmodia
• > 3000 yrs old– Chinese, Assyrian, Indian medical texts
• European wars• European colonialisation• Cinchona bark
H. sapiens and P. falciparum
Hay Nat Comm 2010Fairhurst NEJM 2004
Where was malaria?
memory.loc.gov
How big of a problem is malaria?
Malaria J 2011; 10: 378
P. falciparum
P. vivax
How big of a problem is malaria?
Plos Med 2010; 7: e1000290
How big of a problem is malaria?
Lancet 2012; 379: 2151
U5 deathsTotal: 7.6mMalaria: 564,000
Who gets malaria?People in Africa and S. Asia
Plos Med 2010; 7: e1000290
60%
Who gets malaria?Children
Nat Immunol 2008; 9: 725Lancet 2014 (in press)
Asymptomatic infection
Mild malaria
Severe malaria
?
?
Who gets malaria?Pregnant women
http://www.cdc.gov/malaria/malaria_worldwide/reduction/iptp.htmlPLoS Med 2010; 7(1): e1000221
Who gets malaria?Travelers
MMWR 2012; 61
Malaria today
Who is working on malaria?
How is malaria treated?
Artemisinin combination therapies:e.g. Coartem
Bark of Cinchona tree:Quinine
ChloroquineMefloquine
SP(Fansidar)
Artemisinin combination therapies
New malaria drugs? Sept 2013RegistrationPreclinical
Research Translational DevelopmentLead Opt Phase IIaPhase ILead Gen Phase IVPhase IIb/III
MiniportfolioNovartis
1 ProjectNovartis
Artesunate for injection
Guilin
Coartem®-DNovartis
MiniportfolioGSK
MiniportfolioSanofi
AminopyridinesUCT
Other Projects19 Projects
HeterocyclesCelgene
MiniportfolioAstraZeneca
4 ProjectsGSK
KAE609Novartis
OZ439(Monash/UNMC/
STI)
Azithromycin chloroquine
Pfizer
PyramaxShin Poong/
University of Iowa
OxaborolesAnacor
ELQ-300(USF/
OHSU-VAMC)
21A092(DrexelMed/UW)
KAF156Novartis
DSM265(UTSW/UW/
Monash)
Eurartesim® Sigma-Tau
Whole Cell LeadsAstraZeneca
TafenoquineGSK
P218 DHFR(Biotec/Monash/
LSHTM)
2 ProjectsLiverpool
STM/Liverpool Uni
DHODHUTSW/UW
PyramaxPaediatricShin Poong/
University of iowa
Eurartesim® PaediatricSigma-Tau
Orthologue LeadsSanofi
HeterocyclesDundee
Included in MMV portfolio post registration
SP-AQGuilin
ASAQ Winthropsanofi /DNDi
Nauclea pobeguinii
DRC/Antwerp
Argemone mexicana
Mali/Geneva
MMV390048(UCT)
SJ557733St Jude/Rutgers
Global Malaria Portfolio, 2Q 2014Classified by therapeutic type
ELQ300Takeda(USF/
OHSU-VAMC)
21A092(DrexelMed/UW)
DSM265NIH/Takeda
P218 DHFRBIOTEC(Monash/LSHTM)
MMV048UCT/TIA
RKA182LSTM/Liverpool
NPC-1161-BMississippi
BCX4945Biocryst/Albert Einstein
College of Medicine
SAR116242Palumed
AQ13Immtech
ACT840Actelion
DF02Dilafor
CDRI 97-78Ipca
N-tert butyl isoquine
LSTM/Liverpool/GSK
SJ733St Jude
(Rutgers/NIH)
Artesunate MefloquineCIPLA/DNDi
Artesunate for injection
Guilin
Artemether- LumefantrineDispersible
Novartis
Pyronaridine-ArtesunateShin Poong
Dihydroartemisin- Piperaquine
Sigma-Tau
Artesunate AmodiaquineSanofi /DNDi
Artemether- Lumefantrine
Novartis 1
2
6
7
3
4
5
* First review or approval by WHO Prequalification, or by regulatory bodies who are ICH members or observers
OZ439/FQSanofi
KAE609Novartis
OZ439/PQPSanofi
KAF156Novartis
TafenoquineGSK
Pyronaridine-Artesunate Paediatric
Shin Poong/Iowa
DHA Piperaquine PaediatricSigma-Tau
Sulfadoxine Pyrimethamine +
AmodiaquineGuilin
SAR97276Sanofi
FosmidomycinPiperaquine
Jomaa Pharma GmbH
Methylene Blue /AQHeidelberg
Rectal Artesunate CIPLA/Strides/TDR
ArtemisoneUHKST
Co-trimoxazole Bactrim
Inst. of Trop. Med.
Artemisinin Naphthoquine
KPC
Arterolane/PQPRanbaxy
Artemether sub-lingual spray
ProtoPharma Ltd
8
4
5
9
10
1 Brand name: Coartem®, Generics by Ajanta, Cipla, Ipca, Strides, Macleods Pharma Ltd, Mylan Laboratories2 Brand name: Coartem® Dispersible, Generic by Ajanta3 Brand name: Artesun® 4 Brand name: Eurartesim® 5 Brand name: Pyramax® 6 Brand names: CoarsucamTM, ASAQ/Winthrop®, generics by Ajanta, Ipca, Guilin, Cipla, Strides (co-blistered)7 Also Acino/Mepha product (co-blistered)8 Brand name: SynriamTM
9 Brand name: ARCO® 10 Brand name: ArTiMistTM
Non MMV
Included in MMV portfolio post registration
ACT’s
Endoperoxides
Severe Malaria
Antibiotics
P. vivax
Molecular Mechanisms
Cell Based Mechanisms
Natural Products
On Hold
ResearchResearchLead
optimisationPhase IIa Phase IIb/III
Under review *
DevelopmentPatient
exploratoryPatient
confirmatoryPhase IVPost
Approval
AccessTranslational
PreclinicalHuman
volunteers
MMV121(Dundee)
Number of Preclinical – Phase IV candidates
21
10
20
30
409
4
2
4
8
7
2
Currentpipeline ACT’s Endoperoxide
SevereMalaria
Antibiotics P.vivax MolecularMechanisms
Cell BasedMechanisms
On holdNatural Products
3
0
39
ACT’s
Endoperoxides
Severe Malaria
Antibiotics
P. vivax
Molecular Mechanisms
Cell Based Mechanisms
Natural Products
On Hold
How do we prevent malaria?
Vector insecticide resistance
Parasite drug resistance
Parasite drug resistance
Vector insecticide resistance
Prevention in pregnant women
Lancet ID 2011; 11: 190
Progress?
• “Malaria mortality rates have fallen by more than 25% since 2000”
• “Off 99 countries with ongoing malaria transmission, 43 recorded decreases of more than 50%... Between 2000 and 2010”
• 2004-2010-2012: LLINs 6m 145m 66m• 2010 – 2011: RDTs 88m 155m• 2005-2011: ACTs 11m 278m
WHO, World Malaria Report 2011
Progress?Zanzibar Ethiopia Fajara
Kilifi
Limpopo, SASao Tome &Principe
Bioko I.
Lancet ID 2010; 10: 545
Progress?
Lancet 2008; 372: 1555Lancet 2014 (in press)
What about a vaccine?
Annu Rev Med 2011; 63: 345
Malaria vaccines?
www.malariavaccine.org
What about a vaccine?
NEJM 2011; 365: 1863Plos Med 2014; 11: e1001685
Wall St J 7/24/2014
Drug resistance
Antimalarial Drug
Year Introduced
First Reported
Resistance
Difference (years)
Quinine 1632 1910 278
Mepacrine 1935 1945 10
Chloroquine 1945 1957 12
Proguanil 1948 1949 1
Fansidar 1967 1967 0
Mefloquine 1977 1982 5
Atovaquone 1996 1996 0
Artemisinin 1980 2009 ?
Drug resistance
NEJM 2009; 361: 455NEJM 2014; 371: 411
Drug resistance
Nature 2014; 505: 50JID 2014 (in press)
Drug resistance
JID 2014; 210: 335www.wwarn.org
What’s next?• Preventive measures• Vector control• New drugs
– Combinations– Adjunctive
• Better diagnostics– Surveillance
• New vaccines– Antigens– Adjuvants
• Molecular pathogenesis
Parting words
“Be sure to give the poor the aid they most need. There are a thousand hacking at the branches of evil to one who is striking at the root, and it may be that he who bestows the largest amount of time and money on the needy is doing the most by his mode of life to produce the misery which he strives in vain to relieve.”
-- H.D. Thoreau